MHC Class I: Key Regulator of Immune Response and Cancer Progression

Target Name: Major Histocompatibility Complex Class I

NCBI ID: P44154

Major Histocompatibility Complex Class I

Other Name(s): MHC I Complex

MHC Class I: Key Regulator of Immune Response and Cancer Progression

The Major Histocompatibility Complex (MHC) is a protein complex that plays a crucial role in the immune system. MHC class I is one of the MHCs that are widely studied, and it is known as the major histocompatibility complex class I. MHC class I is a transmembrane protein that is composed of four subunits: alpha, beta, gamma, and delta. The MHC class I protein is expressed in most tissues and cells in the body and is involved in the presentation of antigens to T cells.

MHC class I is a key regulator of the immune response. It is expressed in the antigen-presenting cells (APCs), which are responsible for presenting antigens to T cells. MHC class I helps to determine which antigens are processed and loaded onto the major histocompatibility complex class II (MHC II) molecules, which are then presented to T cells.

MHC class I is also involved in the regulation of the adaptive immune response. It is known to play a role in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). MHC class I molecules have been shown to interact with intracellular signaling pathways, including the T cell receptor (TCR) and the B cell receptor (BCR).

In addition to its role in the immune response, MHC class I is also a potential drug target. Several studies have identified MHC class I as a potential target for small molecules and antibodies, due to its unique structure and the involvement of its immunosuppressive effects ( 4). MHC class I has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and apoptosis.

MHC class I has also been shown to play a role in cancer progression. Studies have shown that MHC class I molecules are expressed in many types of cancer, including breast, ovarian, and colorectal cancers. MHC class I has also been shown to contribute to the development of cancer stem cells.

In conclusion, MHC class I is a complex protein that is involved in the immune response and cancer progression. Its unique structure and role in the regulation of the immune response make it a potential drug target. Further research is needed to fully understand the mechanisms of MHC class I and its potential as a drug target.

Protein Name: Major Histocompatibility Complex Class I

The "Major Histocompatibility Complex Class I Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Major Histocompatibility Complex Class I comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets